Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05965167 |
Recruitment Status :
Active, not recruiting
First Posted : July 28, 2023
Last Update Posted : November 24, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hypoparathyroidism | Drug: EBP05 Drug: Forteo 20 mg Drug: EBP11 Drug: EBP22 | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 45 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1b, Open-label, Partially Randomised Study to Assess Safety and Compare Pharmacokinetics of New Oral hPTH(1-34) Tablet Formulations vs. Oral EBP05 Tablets and Subcutaneous Forteo® Injection in Healthy Male Subjects |
Actual Study Start Date : | May 11, 2023 |
Estimated Primary Completion Date : | March 2024 |
Estimated Study Completion Date : | March 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Treatment A EBP05 2.5 mg
Single dose of oral EBP05 2.5 mg
|
Drug: EBP05
Oral tablets
Other Name: hPTH(1-34) |
Experimental: Treatment B EBP05 1.5 mg
Single dose of oral EBP05 1.5 mg
|
Drug: EBP05
Oral tablets
Other Name: hPTH(1-34) |
Experimental: Treatment C Forteo 20 mg
Single SC injection of Forteo 0.02 mg
|
Drug: Forteo 20 mg
Subcutaneous injection
Other Name: hPTH(1-34) |
Experimental: Treatment D EBP11 1.5 mg
Single dose of oral EBP11 1.5 mg
|
Drug: EBP11
Oral tablets
Other Name: hPTH(1-34) |
Experimental: Treatment E EBP11 BID (dose determined after IA)
Based on PK data from 1st Interim Analysis BID administration of oral EBP11. The selected BID dose to be administered will be either 1.5, 2.0 or 2.5 mg.
|
Drug: EBP11
Oral tablets
Other Name: hPTH(1-34) |
Experimental: Treatment F EBP11 BID (dose determined after IA)
BID administration of oral EBP11 tablets 1.5 mg tablets (3 x 0.5 mg tablets) as first dose and 2.5 mg (5 x 0.5 mg tablets) as second dose.
|
Drug: EBP11
Oral tablets
Other Name: hPTH(1-34) |
Experimental: Treatment G EBP11 1.5 mg
Single dose of oral EBP11 1.5 mg
|
Drug: EBP11
Oral tablets
Other Name: hPTH(1-34) |
Experimental: Treatment I EBP22 1.5 mg
Single dose of oral EBP22 1.5 mg
|
Drug: EBP22
Oral tablets
Other Name: hPTH(1-34) |
Experimental: Treatment J EBP22 1.5 mg
Single dose of oral EBP22 1.5 mg
|
Drug: EBP22
Oral tablets
Other Name: hPTH(1-34) |
Experimental: Treatment K oral EBP formulation determined based on IA results
Single dose of oral 1.5 mg of the selected oral formulation (EBP11 or EBP22) based on the results of all Cohort 1 and 2 Interim Analyses
|
Drug: EBP11
Oral tablets
Other Name: hPTH(1-34) Drug: EBP22 Oral tablets
Other Name: hPTH(1-34) |
Experimental: Treatment L BID of oral EBP formulation determined based on IA results
BID dose of oral 1.5 mg of the selected oral formulation (EBP11 or EBP22) based on the results of all Cohort 1 and 2 Interim Analyses
|
Drug: EBP11
Oral tablets
Other Name: hPTH(1-34) Drug: EBP22 Oral tablets
Other Name: hPTH(1-34) |
Experimental: Treatment M BID of EBP05 2.5 mg
BID dose of oral EBP05 2.5 mg
|
Drug: EBP05
Oral tablets
Other Name: hPTH(1-34) |
Experimental: Treatment N single dose of Treatment K
Single dose of Treatment K
|
Drug: EBP11
Oral tablets
Other Name: hPTH(1-34) Drug: EBP22 Oral tablets
Other Name: hPTH(1-34) |
Experimental: Treatment H EBP22 2.5 mg (5 x 0.5 mg).
Singe dose of oral EBP22 2.5 mg (5 x 0.5 mg).
|
Drug: EBP22
Oral tablets
Other Name: hPTH(1-34) |
- Assessment of the pharmacokinetic profile of plasma hPTH(1-34) after single or twice daily oral administration for treatment regimen as listed under Arms and Interventions at 5, 10, 15, 20, 40, 50, 60, 75, 90, 105, 120, 180, 240, 360 min. post dose [ Time Frame: 6 hours ]Pharmacokinetic parameter - plasma hPTH(1-34) in pg/mL
- Calculation of plasma levels of hPTH(1-34) AUC0-t for each treatment regimen [ Time Frame: 6 hours ]Pharmacokinetic parameter - total drug exposure at different time points up to 360 min. post dose
- Calculation of plasma levels of hPTH(1-34) AUC0-inf for each treatment regimen [ Time Frame: 6-14 hours ]Pharmacokinetic parameter - total drug exposure in pg/mL over time from 0 extrapolated to infinity
- Calculation of plasma levels of hPTH(1-34) AUC%extrap for each treatment regimen [ Time Frame: 6-14 hours ]Pharmacokinetic parameter - Percent of AUC0-inf extrapolated to confirm reliability
- Calculation of plasma levels of hPTH(1-34) Cmax for each treatment regimen [ Time Frame: 6-14 hours ]Pharmacokinetic parameter - hPTH (1-34) maximal concentration in pg/mL (Cmax)
- Calculation of plasma levels of hPTH(1-34) Tmax for each treatment regimen [ Time Frame: 6-14 hours ]Pharmacokinetic parameter - time in minutes to reach max. concentration of hPTH(1-34)
- Calculation of plasma levels of hPTH(1-34) Kel for each treatment regimen [ Time Frame: 6 hours ]Pharmacokinetic parameter - elimination rate constant in pg/mL, fraction of drug eliminated per time-point up to 360 min. post dose
- Calculation of plasma levels of hPTH(1-34) t½ for each treatment regimen [ Time Frame: 6-14 hours ]Pharmacokinetic parameter - terminal elimination half life of hPTH(1-34) in minutes
- Calculation of plasma levels of hPTH(1-34) Tlast for each treatment regimen [ Time Frame: 6-14 hours ]Pharmacokinetic parameter - time of the last measurable concentration of hPTH(1-34) in minutes
- Assessment of inter-subject variability of hPTH(1-34) for each treatment regimen [ Time Frame: 6-14 hours ]Pharmacokinetic parameter - Coefficient of Variance (CV%) of hPTH (1-34)
- Calculation of dose proportionality for hPTH(1-34) for relevant treatment regimen [ Time Frame: 6 hours ]Pharmacokinetic parameter
- Assessment of the duration of exposure to hPTH(1-34) in minutes [ Time Frame: 6 hours ]Pharmacokinetic parameter - up to 360 min. post dose
- Vital Signs - body temperature (Celsius) [ Time Frame: 6 hours ]Safety parameter (group mean at each time point up to 360 min. post dose)
- Vital Signs - respiratory rate (breaths per minute) [ Time Frame: 6 hours ]Safety parameter (group mean at each time point up to 360 min. post dose)
- Vital Signs - blood pressure (systolic/diastolic mmHg) [ Time Frame: 6 hours ]Safety parameter (group mean at each time point up to 360 min. post dose)
- Vital Signs - heart rate (beats per minute) [ Time Frame: 6 hours ]Safety parameter (group mean at each time point up to 360 min. post dose)
- Incidence of Treatment-Emergent Adverse Events as assessed by the Principle Investigator [ Time Frame: 6-14 hours ]Safety parameter - AEs observed over duration of study participation
- Incidence of Serious Adverse Events (SAEs) as assessed by the Principle Investigator [ Time Frame: 6-14 hours ]Safety parameter - SAEs observed over duration of study participation
- Measurement of plasma soybean trypsin inhibitor, Kunitz type (SBTI) levels (EBP05 only) [ Time Frame: 6 hours ]Pharmacokinetic parameter in ng/mL
- Measurement of plasma salcaprozate sodium (SNAC) levels (EBP05 only) [ Time Frame: 6 hours ]Pharmacokinetic parameter in μg/mL
- Measurement of serum calcium (albumin-corrected total calcium) for all treatment regimen [ Time Frame: 6 hours ]Pharmacodynamic parameter in mg/dL at 120, 240, 360 min post dose
- Measurement of serum phosphate for all treatment regimen [ Time Frame: 6 hours ]Pharmacodynamic parameter in mg/dL at 120, 240, 360 min post dose
- Measurement of serum intact hPTH(1-84) for all treatment regimen [ Time Frame: 6 hours ]Pharmacodynamic parameter in pg/mL at 120, 240, 360 min post dose
- Measurement of serum 1,25-(OH)2D for all treatment regimen (optional) [ Time Frame: 6 hours ]Pharmacodynamic parameter in ng/mL at 120, 240, 360 min post dose
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 35 Years (Adult) |
Sexes Eligible for Study: | Male |
Gender Based Eligibility: | Yes |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy male subjects, 18 - 35 years of age, inclusive, at screening.
- Continuous nonsmoker who has not used nicotine containing products (including e-cigarettes, vapors, etc.) for at least 12 months prior to first dosing and throughout the study, based on subject self-reporting.
- Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at screening.
- Medically healthy with no clinically significant medical condition, physical examination, laboratory profiles, vital signs, orthostatic vital sign measurements, or ECGs, as deemed by the PI or designee to be relevant to the study and does not pose an additional risk to the subject by their participation in the study.
- Understands the study procedures described in the Informed Consent Form (ICF), be willing and able to comply with the protocol, and provides written consent.
Exclusion Criteria:
- History or current condition of mental instability or cognitive impairment that, in the opinion of the investigator, could compromise the validity of informed consent, compromise the safety of the participant, or lead to nonadherence with the study protocol or inability to conduct the study procedures.
- Active gastrointestinal inflammatory disorder, gastrointestinal motility disorders, and chronic gastritis, including but not limited to: ulcerative colitis, Crohn's disease, irritable bowel syndrome, short bowel syndrome, celiac disease, gastroparesis, that may affect drug bioavailability.
- Any conditions or factors that, in the judgment of the PI or designee, somehow may impact gastrointestinal absorption, distribution or metabolism of parathyroid hormone analogues, or known to potentiate or predispose to undesired effects.
- History of significant gastrointestinal, liver or kidney disease, or gastrointestinal surgery (including bariatric surgery, or any other interventional procedures with stomach and intestinal tract) that may affect either drug bioavailability, or hPTH(1-34) or SNAC metabolism.
- History or presence of alcohol or drug abuse or positive urine drug or blood alcohol results at screening.
- Known allergies or sensitivities to components of the Study Medication (e.g. soy) or known hypersensitivity to PTH or hPTH(1-34).
-
History or presence of clinically significant:
- Urolithiasis;
- Angina at Screening, in the opinion of the PI;
- Hypocalcemia or hypercalcemia at screening;
- Personal or family history of congenital long QT syndrome or known family history of sudden death.
-
Subjects with ECG findings deemed abnormal with clinical significance by the PI or designee at screening for the following:
- QTcF interval > 470 msec;
- PR > 220 msec;
- QRS > 120 msec.
- Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).
- Seated blood pressure is less than 90 systolic or 40 diastolic mmHg or greater than 140 systolic or 90 diastolic mmHg at screening;
- Orthostatic vital sign results with a decrease in systolic > 20 mmHg or decrease in diastolic > 10 mm Hg, and/or increase in heart rate of > 20 beats per minute at screening or Day 1 check-in.
- Seated heart rate is lower than 50 bpm or higher than 99 bpm at screening (when clinically significant as determined by PI).
- Estimated creatinine clearance < 80 mL/min at screening
-
Unable to refrain from or anticipates the use of:
- Any drug, including prescription and nonprescription medications, herbal remedies, or vitamin supplements that should be taken on the treatment visit day before the dosing of Study Medication and 2 hours after the dosing of Study Medication.
- H2 blocker or PPI or antacid (including prescription and nonprescription) three days before the dosing of the Study Medication and 2 hours after the dosing of Study Medication.
- Donation of blood or significant blood loss within 56 days prior to first dosing.
- Hemoglobin levels below 13 g/dL at screening or at in screening test done during the study.
- Plasma donation within 7 days prior to first dosing.
- Participation in another interventional clinical study within 30 days prior to screening visit.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05965167
Israel | |
Clinical Research Center Hadassah Ein Kerem Medical Center | |
Jerusalem, Israel, 91120, |
Study Director: | Arthur C Santora, MD | Entera Bio Chief Medical Officer |
Responsible Party: | Entera Bio Ltd. |
ClinicalTrials.gov Identifier: | NCT05965167 |
Other Study ID Numbers: |
ENT-11-2023 |
First Posted: | July 28, 2023 Key Record Dates |
Last Update Posted: | November 24, 2023 |
Last Verified: | November 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Hypoparathyroidism PTH(1-34) Parathyroid Hormone Teriparatide |
Hypoparathyroidism Parathyroid Diseases Endocrine System Diseases Teriparatide |
Calcium-Regulating Hormones and Agents Physiological Effects of Drugs Bone Density Conservation Agents |